Novartis receives FDA approval for Beovu®, offering wet AMD patients a new option

  • 0

Novartis receives FDA approval for Beovu®, offering wet AMD patients a new option

Basel, October 8, 2019 — Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu® (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD)[1]. Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase[1] with uncompromised efficacy.

Read the full press release

Summary
Author Rating
1star1star1star1star1star
Aggregate Rating
no rating based on 0 votes
Brand Name
Novartis
Product Name
Beovu

About Author

Louis Lipschultz

Dr. Lipschultz purchased what is now Southland Eye Associates, PC from Dr. Sol Rocke, in 1986. They enjoyed practicing together year after year, until Dr. Rocke's passing in 2010 at the age of 90. Dr. Lipschultz has been highly active in both optometric practice and industry. He was on the Advisory Board of Bausch and Lomb for many years, and has participated in market and clinical research projects from multiple companies. His passions in practice bridge the gamut of vision care issues: advanced contact lens fitting, detecting and managing diseases such as macular degeneration and glaucoma, as well as vision disorders in children.

Schedule an Appointment


Find a Doctor on ZocDoc

Subscribe